Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease

Anemia of Chronic Kidney Disease Clinical Trial

— D-fense  

Official title:

Cholecalciferol as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01532349
• Other study ID #: NA_00066175
• Secondary ID: 1K23DK084116-01A
• Status: Recruiting
• Phase: Phase 2
• First received: February 8, 2012
• Last updated: September 19, 2013
• Start date: May 2012

Study information

• Verified date: September 2013
• Source: Johns Hopkins University
• Contact: Meredith Atkinson, MD
• Phone: 410-955-2467
• Email: matkins3[@]jhmi.edu
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This research is being done to study the effectiveness of vitamin D (cholecalciferol) to modify hepcidin levels in children with chronic kidney disease (CKD). Anemia is a common problem in children with CKD. Anemia is when the body does not have enough healthy red blood cells. Hepcidin is a protein in the blood which interferes with the body's production of red blood cells. This study will see if vitamin D lowers hepcidin levels in children and young adults with CKD. If so, it could be used as an additional treatment for anemia in these children, in addition to the current therapies already in use including iron supplements and erythropoietin. People between the ages of 1 and 21 with CKD may be considered for this study.

Description:

Vitamin D Supplementation is a practical and inexpensive intervention which is safe, readily available and clinically indicated. Substantial recent evidence suggests vitamin D may modify inflammatory pathways in CKD. There is a high probability of benefit and a low probability of harm for this easily modifiable factor. 25D levels can be effectively modified through oral supplementation with cholecalciferol. To the best of our knowledge, no studies examining the effects of oral cholecalciferol supplementation on hepcidin levels have been conducted in children with either CKD or other diseases.

We will conduct a randomized open-label controlled trial of oral cholecalciferol supplementation in children aged 1-21 years with stage 2-5 (pre-dialysis) CKD receiving regular nephrology follow-up at a tertiary-care children's hospital (Johns Hopkins Children's Center). The intervention model will be parallel assignment. Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency, or will be treated with 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance.(1) Allocation will be double-blinded to prevent knowledge of allocation status affecting interpretation of results. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.(1) We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for > 1 year with no evidence of vitamin D toxicity.(2) 25D levels between 40 and 80 are indicative of "sufficiency", and a safe upper limit of intake, in which the risk of hypercalcemia is negligible, has been defined as 10,000 IU/day.(3, 4) Cholecalciferol will be provided in both tablet (vitamin D 2000 IU tablets and 400 IU tablets, National Vitamin Company, Casa Grande, AZ) and liquid (Enfamil® D-Vi-Sol™ Drops, 400 IU per mL) form, based on the ability to tolerate and preference of the subject.

Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.

Data Safety Monitoring Board will review serum calcium, phosphorus, and urine calcium:creatinine ratio values at the one month visit; if subjects show evidence of hypercalcemia or hyperphosphatemia (serum values > upper limit of normal, age-specific values, see Table 3 below), study drug will be discontinued.(3) If subjects demonstrate evidence of hypercalciuria (urine calcium:cr ratio > 0.6 in 1-2 year olds or > 0.2 in > 2 year olds) study drug will be discontinued.(5) In addition, if 25-hydroxy vitamin D levels > 80 ng/mL are reached, the study drug will be discontinued. In any subject in whom study drug is discontinued, the 3-month laboratory data will still be collected.

In the case of hypoalbuminemia (serum albumin < 3.5 g/dL) corrected total serum calcium will be calculated using the formula: Corrected calcium (mg/dL) = serum calcium (mg/dL) + 0.8 (4

• serum albumin [g/dL])(2) Standardized blood pressure measurement will include three manual BP measurements conducted after five minutes of rest with an aneroid sphygmomanometer, at least 30 seconds apart.

1. KDOQI Work Group. KDOQI clinical practice guideline for nutrition in children with CKD:

2008 update. executive summary. Am J Kidney Dis. 2009 Mar;53(3 Suppl 2):S11-104.

2. KDOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2005;46(Supplement 1):S1-S122.

3. Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: In search of the therapeutic window. Pediatr Nephrol. 2010 Jun 22.

4. Shroff R, Knott C, Rees L. The virtues of vitamin D--but how much is too much? Pediatr Nephrol. 2010 Sep;25(9):1607-20.

5. Kruse K, Kracht U, Kruse U. Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents. Eur J Pediatr. 1984 Nov;143(1):25-31.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 21 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of stage 2-5 Chronic Kidney Disease (estimated glomerular filtration rate [GFR] between 15 and < 90 ml/min/1.73m2) based on the new bedside Schwartz formula estimation using serum creatinine and height [height in cm x 0.413/serum creatinine]

• 1-21 years of age

• Willingness and ability to provide informed consent and assent

Exclusion Criteria:

• Children less than 1 year of age (in whom risk of vitamin D toxicity may be increased) or greater than 21 years at time of study screening

• Children with a documented history of hypercalcemia or nephrolithiasis

• Children with GI tract discontinuity (ostomy)

• Current pregnancy or pregnancy within the last 12 months

• Children with known anemia-related disorders including sickle cell anemia, thalassemia

• Children with severe 25D deficiency (< 5 ng/mL) likely to be associated with severe morbidity and requiring prompt high dose vitamin D supplementation, or with 25D levels > 60 ng/mL which could be associated with increased risk of vitamin D toxicity

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia of Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Cholecalciferol
Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for > 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.

Locations

Country	Name	City	State
United States	Johns Hopkins University	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in serum hepcidin with vitamin D intervention for children with chronic kidney disease	The null hypothesis to be tested is that Vitamin D supplementation will not be associated with a decrease in serum hepcidin over the study period. Statistical analysis will be performed as intention-to-treat.	three months	No